Drugs / Lanifibranor
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06126562 | Oct → Nov 2023 | — | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03866369 | Jan → Aug 2019 | — | Inventiva Pharma | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05232071 | Jun 2022 → May 2024 | metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus | Inventiva Pharma | Completed | No outcome recorded |
| Phase 2 | NCT03008070 | Feb 2017 → Feb 2020 | metabolic dysfunction-associated steatohepatitis | Inventiva Pharma | Completed | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT04849728 | Aug 2021 → Sep 2027 expected | metabolic dysfunction-associated steatohepatitis | Inventiva Pharma | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT03459079 Comparator | Aug 2018 → Apr 2023 | NAFLD1, type 2 diabetes mellitus | University of Florida | Completed | No outcome recorded |
| Phase 2 | NCT02503644 Comparator | Oct 2015 → Oct 2018 | diffuse cutaneous systemic sclerosis, diffuse scleroderma | Inventiva Pharma | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lanifibranor | “Lanifibranor (IVA337), a panPPAR agonist, by acting on these three different PPAR isotypes, combines pharmacological effects that could address the different components of the...” PMID 33038502 ↗ Oct 2020 |
| Known as | IVA337 | “Multiple Ascending Dose Phase I Study in Order to Define Lanifibranor (IVA337) Supra-thjerapeutic Dose” NCT03866369 ↗ |
| Action | Activate | “IVA337 (lanifibranor) is a next generation pan-PPAR (peroxisome proliferator-activated receptors) agonist addressing the pathophysiology of NASH : metabolic, inflammatory and fibrotic.” NCT03008070 ↗ |
| Modality | Small molecule | — CHEMBL4091374 ↗ |
| Route | Oral | “Single daily oral dose during 14 days” NCT03866369 ↗ |